Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.51 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.41 |
| ▸ | METAP2 | P50579 | 3/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383280 | 1.00 | AXL (0.59) | AXLTRPA1NOS1TRPM8METAP2 | |
| SCHEMBL7922208 | 0.79 | AXL (0.59) | AXLTRPA1NOS1TRPM8METAP2 | |
| SCHEMBL22967876 | 0.76 | AXL (0.56) | AXLTRPA1NOS1TRPM8METAP2 | |
| SCHEMBL29493856 | 0.76 | NOS1 (0.50) | AXLTRPA1NOS1METAP2CSNK2A1 | |
| SCHEMBL2005532 | 0.76 | NOS1 (0.50) | AXLTRPA1NOS1METAP2CSNK2A1 | |
| SCHEMBL28799165 | 0.75 | NOS1 (0.50) | AXLTRPA1NOS1METAP2CSNK2A1 | |
| SCHEMBL29980240 | 0.75 | NOS1 (0.50) | AXLTRPA1NOS1METAP2CSNK2A1 | |
| SCHEMBL23043392 | 0.75 | TRPA1 (0.45) | AXLTRPA1NOS1TRPM8METAP2 | |
| SCHEMBL30959578 | 0.75 | TDO2 (0.47) | AXLTRPA1NOS1TRPM8METAP2 | |
| SCHEMBL31642824 | 0.75 | AXL (0.46) | AXLTRPA1NOS1TRPM8METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2020047192-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AXL 4091/4885TRPA1 4503/4885NOS1 4612/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | AXL 4091/4885TRPA1 4503/4885NOS1 4612/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | AXL 4091/4885TRPA1 4503/4885NOS1 4612/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | AXL 2654/4885TRPA1 4540/4885NOS1 4548/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AXL 4091/4885TRPA1 4503/4885NOS1 4612/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AXL 1250/4885TRPA1 1442/4885NOS1 4737/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AXL 4091/4885TRPA1 4503/4885NOS1 4612/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AXL 4091/4885TRPA1 4503/4885NOS1 4612/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AXL 4091/4885TRPA1 4503/4885NOS1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.